ES2066012T3 - Metodo para el diagnostico de tumores. - Google Patents

Metodo para el diagnostico de tumores.

Info

Publication number
ES2066012T3
ES2066012T3 ES89870058T ES89870058T ES2066012T3 ES 2066012 T3 ES2066012 T3 ES 2066012T3 ES 89870058 T ES89870058 T ES 89870058T ES 89870058 T ES89870058 T ES 89870058T ES 2066012 T3 ES2066012 T3 ES 2066012T3
Authority
ES
Spain
Prior art keywords
tumors
diagnosis
growth factor
factor receiver
nervios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89870058T
Other languages
English (en)
Inventor
Eugene Malcolm Johnson Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of ES2066012T3 publication Critical patent/ES2066012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

SE DESCRIBE UN METODO DE DIAGNOSTICO IN VITRO PARA DETERMINAR LA PRESENCIA DE RECEPTOR DE FACTOR DE CRECIMIENTO DE NERVIOS QUE PRODUCEN TUMORES, EL CUAL CONSISTE EN DETERMINAR LA PRESENCIA DE UN ELEVADO NIVEL DE UN RECEPTOR DE FACTOR DE CRECIMIENTO DE NERVIOS MUTILADOS EN UNA MUESTRA DE UN FLUIDO CORPORAL DE UN PACIENTE AFLIGIDO POR TAL TUMOR.
ES89870058T 1988-05-26 1989-04-21 Metodo para el diagnostico de tumores. Expired - Lifetime ES2066012T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/198,948 US4855241A (en) 1988-05-26 1988-05-26 Tumor diagnostic method

Publications (1)

Publication Number Publication Date
ES2066012T3 true ES2066012T3 (es) 1995-03-01

Family

ID=22735562

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89870058T Expired - Lifetime ES2066012T3 (es) 1988-05-26 1989-04-21 Metodo para el diagnostico de tumores.

Country Status (8)

Country Link
US (1) US4855241A (es)
EP (1) EP0344139B1 (es)
JP (1) JP2837872B2 (es)
AT (1) ATE117090T1 (es)
CA (1) CA1340068C (es)
DE (1) DE68920477T2 (es)
ES (1) ES2066012T3 (es)
GR (1) GR3015058T3 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US5100774A (en) * 1988-04-22 1992-03-31 The Wistar Institute Of Anatomy & Biology Methods for detecting growth factor receptor expression
JPH06503722A (ja) * 1990-11-30 1994-04-28 アボット・ラボラトリーズ 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体
US6613506B1 (en) 2000-11-28 2003-09-02 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
GB9902659D0 (en) * 1999-02-05 1999-03-31 Microbiological Res Authority Assay with reduced background
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
NZ600339A (en) * 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786593A (en) * 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4707443A (en) * 1985-04-19 1987-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same

Also Published As

Publication number Publication date
GR3015058T3 (en) 1995-05-31
EP0344139B1 (en) 1995-01-11
JPH0225751A (ja) 1990-01-29
ATE117090T1 (de) 1995-01-15
DE68920477D1 (de) 1995-02-23
JP2837872B2 (ja) 1998-12-16
US4855241A (en) 1989-08-08
EP0344139A2 (en) 1989-11-29
EP0344139A3 (en) 1990-09-26
DE68920477T2 (de) 1995-07-20
CA1340068C (en) 1998-10-06

Similar Documents

Publication Publication Date Title
EP0970724A3 (en) Tumour treatment apparatus
PT912898E (pt) Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg
MX168468B (es) Procedimiento para la obtencion de (+)1r-trans-2,2 dimetil-3-(2,2-diclorovinil)-ciclopropan-carboxilato de 2,3,5,6-tetrafluorbencilo
FI800706A7 (fi) Kehon kudokseen, erityisesti luukudokseen istutettava elin.
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
DE3751809D1 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
IT7919003A0 (it) Procedimento per la fabbricazione di impiantati nonche' impiantati realizzati con detto procedimento.
ES8605971A1 (es) Una protesis vascular que tiene una estructura tubular tricotada integrada
ES2183815T3 (es) Quimioterapia para el cancer.
ES8303404A1 (es) Procedimiento para preparar 3-amino-sidnoniminas sustituidas.
FI891718A0 (fi) Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer.
AR001073A1 (es) Benzoilguanidinas basicamente sustituidas procedimientos para su preparación su empleo como medicamento o agente de diagnostico asi como medicamento que las contiene
ES2069892T3 (es) Complejos de ciclopentadienilcarbonilo-99mtc, procedimiento para su preparacion asi como su utilizacion en el diagnostico.
ES8107021A1 (es) Un procedimiento para preparar una solucion oftalmica que contiene una sal de 2-acetil-7-(2-hidroxi-3-isopropilamino- propoxi) benzofurano.
Seneca et al. The in vitro production of cortisone by mammalian cells
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
BR0009573A (pt) Composições e métodos para o tratamento e diagnose do câncer de mama
ES509412A0 (es) Un aparato generador de sonidos artificiales para uso por un huesped vivo.
MX9300139A (es) Dispositivo de liberacion sostenida implantable.
EP0282018A3 (en) Process for isolating basal membrane proteins from human or animal tissues
IL155135A (en) Apparatus for prostate cancer diagnosis
GR3015058T3 (en) Tumor diagnostic method.
ES2093612T3 (es) Neoglucoproteinas, su preparacion y empleo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 344139

Country of ref document: ES